Exit

According to a survey carried out by Veeva Systems in 2015[1], more than 60% of pharma companies is not completely ready to meet the EFPIA transparency requirements.

From June 2016, all pharma companies in EFPIA member countries, European Federation of Pharmaceutical Industries and Associations, will have to publish their transfers of values to HCPs and HCOs: registration, hospitality and consultancy fees, donations and grants… The first disclosure will be made by 30 June 2016 for payments made in 2015. This information will be published on a public platform, whether on the company’s website or on a central platform.

Being able to efficiently collect, organize and publish such an amount of data represents a major challenge for European pharma companies. “More than half of European companies surveyed say they do not have the most current, accurate customer data in key systems, including aggregate spend systems (56%), travel and expense systems (55%) and enterprise resource planning (ERP) systems (53%), which will be critical for accurately reporting payments made to physicians across the continent” [2], explains Guillaume Roussel, director of strategy for Veeva OpenData in Europe.

Moreover, in some countries, pharma companies must obtain the HCP/HCO consent before publishing the payments. “We know from market research that HCPs are broadly in support of this initiative but despite industry communications, they may still have reservations about the implications of disclosure” [3], says David Morrow, Head of Medical Excellence in the UK and Ireland at AstraZeneca. Indeed, in the UK Healthcare Professionals Support Transparency on Pharma Payments.

But, according Andy Powrie-Smith, director of communications at the EFPIA, the figures should be considered with forethought: “We have companies organizing a lot of data, across a lot of markets with a lot of staff that need training. What we are hearing from companies is that this is a big project, we need to be ready by June 2016, we are not ready yet but we will get there.” [4]

.

[1] http://www.thepharmaletter.com/article/more-than-two-thirds-of-companies-not-ready-for-efpia-disclosure-code-survey-says
[2] http://www.thepharmaletter.com/article/more-than-two-thirds-of-companies-not-ready-for-efpia-disclosure-code-survey-says
[3] http://www.pharmatimes.com/Article/15-03-19/Disclosure_a_real_opportunity_for_the_industry.aspx
[4] http://www.thepharmaletter.com/article/more-than-two-thirds-of-companies-not-ready-for-efpia-disclosure-code-survey-says
Close
Go top